WHO Raises Concern Over Severe Lack of Obesity Injections

Under 10% of people who could benefit from GLP-1 drugs like Wegovy have access to them, warns the WHO as it issues its first advice on the therapies.

With over a billion people worldwide currently living with obesity, it is advocating for increased and just access to these injectable treatments.

According to forecasts, more than two billion are projected to be obese by 2030 if no action is taken.

"The latest guidelines acknowledges that excess weight is a long-term condition that can be managed with comprehensive and ongoing care," stated the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and logistical bottlenecks are significant barriers to widespread availability to the treatments that can help people shift considerable weight, explains the organization.

GLP-1 Therapy Shortage

Even under the present most optimistic outlook, the manufacturing of GLP-1 therapies could only cover about 100 million people – fewer than 10% of the global need, per the WHO.

The guideline encourages governments and firms to increase availability, via measures such as licensing agreements.

Exclusive production rights on a key compound – the primary component of the drug Wegovy – is scheduled to end in multiple nations in 2026.

How Obesity Drugs Work

The injections imitate a biological compound to reduce digestion speed, curb appetite and boost the sense of being full so individuals consume fewer calories.

Individuals typically see weight reduction after several weeks of commencing the once-weekly jabs.

Studies suggests patients may regain a significant portion within a year of stopping the treatment, because their typical appetite come back.

Being carrying excess weight raises your chance for experiencing diseases, including type 2 diabetes, cardiovascular issues, brain attack, and specific cancers.

Obesity impacts individuals in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, as per the health agency.